iBio Inc.

News & Events

Press Releases

In The Media

1. iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

   GlobeNewswire JUN 24, 2025 7:00 AM EDT
   Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mou...
   READ ARTICLE

2. iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

   GlobeNewswire JUN 23, 2025 4:15 PM EDT
   Review of promising Myostatin and Activin E antibody data iBio to announce 3 rd ...
   READ ARTICLE

3. iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

   GlobeNewswire JUN 16, 2025 7:00 AM EDT
   iBio nominates IBIO-610 as development candidate for its first-in-class Activin E antibody ...
   READ ARTICLE

4. iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

   GlobeNewswire MAY 5, 2025 8:00 AM EDT
   Activin E antibody demonstrates significant decrease in fat in obese mice by reducing visceral fa...
   READ ARTICLE

5. iBio Reports Fiscal Third Quarter 2025 Financial Results

   GlobeNewswire MAY 2, 2025 8:00 AM EDT
   SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq:IBIO), today reported financial re...
   READ ARTICLE

6. iBio Raises $6.2 Million Through Warrant Inducement Transaction

   GlobeNewswire APR 29, 2025 1:43 PM EDT
   SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO) (“iBio” or ...
   READ ARTICLE

7. iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

   GlobeNewswire APR 22, 2025 8:00 AM EDT
   SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Bio, Inc. (Nasdaq: IBIO), an AI-driven innovato...
   READ ARTICLE

8. iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

   GlobeNewswire APR 7, 2025 7:00 AM EDT
   Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-actin...
   READ ARTICLE

9. iBio to Begin Trading on the Nasdaq Stock Exchange

   GlobeNewswire FEB 19, 2025 4:05 PM EST
   SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innova...
   READ ARTICLE

10. iBio Reports Fiscal Second Quarter 2025 Financial Results

    GlobeNewswire FEB 10, 2025 4:05 PM EST
    SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), today reported financial re...
    READ ARTICLE